Get the Stockscreener App
1.89
2.16%
0.04
After Hours:
1.86
-0.03
-1.59%
Foghorn Therapeutics Inc stock is traded at $1.89, with a volume of 347.03K.
It is up +2.16% in the last 24 hours and down -54.13% over the past month.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
See More
Previous Close:
$1.85
Open:
$1.87
24h Volume:
347.03K
Relative Volume:
0.34
Market Cap:
$112.24M
Revenue:
$30.91M
Net Income/Loss:
$-74.28M
P/E Ratio:
-1.5513
EPS:
-1.2183
Net Cash Flow:
$-86.15M
1W Performance:
-5.03%
1M Performance:
-54.13%
6M Performance:
-61.19%
1Y Performance:
-57.24%
1-Day Range:
$1.82
$1.91
1-Week Range:
$1.80
$2.00
52-Week Range:
$1.79
$7.61
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
1.89 | 112.24M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-26 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-02-26 | Downgrade | TD Cowen | Buy → Hold |
| Oct-02-26 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-17-26 | Resumed | Jefferies | Buy |
| Dec-18-25 | Initiated | BTIG Research | Buy |
| Nov-07-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Resumed | B. Riley Securities | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Foghorn: Downgrade "Sell" Eli Lilly Exit FHD-909 And Shift To Preclinical Assets - Seeking Alpha
A more-than-10% owner reports $0.0001 warrants in Foghorn Therapeutics (FHTX). - Stock Titan
A 9.99% cap blocked warrant exercise as BVF reported a stake in Foghorn Therapeutics (FHTX). - Stock Titan
Today's US Stock Gap Movers: DAICW, NXL Lead Gap-Ups; FHTX Leads Gap-Downs - ChartMill
Guggenheim cuts Foghorn Therapeutics price target on drug setback By Investing.com - Investing.com South Africa
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data - Pharmaceutical Executive
Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt - Investing.com
Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt - Investing.com Canada
Guggenheim cuts Foghorn Therapeutics price target on drug setback - Investing.com
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift By Investing.com - Investing.com South Africa
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift - Investing.com
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift By Investing.com - Investing.com UK
Foghorn lays off 40% of staff after Lilly collaboration ends - biospace.com
Thursday's session: gap up and gap down stocks - ChartMill
FHTX Stock Slides As Traders Focus On Cash Runway And Charts - StocksToTrade
FHTX Stock Slides As Traders Eye Key Support Levels - timothysykes.com
FHTX Stock Slides As Traders Eye Key Support Levels - Timothy Sykes
Why is Foghorn Therapeutics stock plummeting today? - Investing.com
Citizens reiterates Foghorn Therapeutics stock rating on trial data - Investing.com
Foghorn Therapeutics (FHTX) Slips 2.17% to $5.87 as Shares Approach Key Support ZoneStock Buy Zone - dars.gov.et
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Price to book forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Precision Trading with Foghorn Therapeutics Inc. (FHTX) Risk Zones - Stock Traders Daily
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet - Yahoo Finance
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 - Investing.com
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com UK
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 - Investing.com
Foghorn Therapeutics (FHTX) Slips 3.5% as Shares Test Key Support Near $5.95Low Vol Factor - vinanet.vn
Foghorn Therapeutics (FHTX) Slips 3.5% as Shares Test Key Support Near $5.95NHNL Divergence - dars.gov.et
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Foghorn Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FHTX | US3441741077 - marketscreener.com
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts - simplywall.st
News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts - simplywall.st
Enterprise value to EBIT forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
HC Wainwright Issues Negative Outlook for FHTX Earnings - MarketBeat
Foghorn Therapeutics Inc (NASDAQ: FHTX) Stock Price, News & Analysis - kalkine.ca
Foghorn Therapeutics Inc (NASDAQ: FHTX) Stock Price, News & Analysis - Kalkine
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade - Yahoo Finance
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade - Zacks Investment Research
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to Hold - MarketBeat
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and Mail
BTIG Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Discipline and Rules-Based Execution in FHTX Response - Stock Traders Daily
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):